天然产物/朝藿定B|cas:110623-73-9|西域试剂

天然产物/朝藿定B,≥98%

产品编号：西域质检-TM44140| CAS NO：110623-73-9| 分子式：C₃₈H₄₈O₁₉| 分子量：808.776

朝藿定B (Epimedin B)是淫羊藿中的一种天然活性成分，据报道有抗骨质疏松症的潜能。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
西域质检-TM44140		￥435.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

天然产物/朝藿定B

Reference Material

This certificate is designed in accordance with ISO 17034 and ISO Guide 31. This reference material (RM) was designed,produced and verified in accordance with ISO/IEC 17025, ISO 17034 and a registered quality management system ISO 9001.

Product Name(产品名称) Epimedin B(朝藿定B)

Product Code(产品编号) 723025-20mg

Lot Number(产品批号) -

CAS No. 110623-73-9

Mol. Weight(分子量) 808.78

Mol. Formula(分子式) C₃₈H₄₈O₁₉

Melting Point(熔点) N/A

Expiry Date(失效日期) -

Boiling point(沸点) N/A

Appearance(外观) Yellow Solid
(黄色固体)________

Storage Temp(存储条件) (2~8)℃,Keep in the shade
冷藏(2~8)℃,置于阴凉处

C E R T I F I E D

Purity

99.6%

C E R T I F I E D

Expanded Uncertainty (U)

0.8%

Uncertainty

The certified value(s) and uncertainty(ies) are determined in accordance with ISO 17034 with an 95% confidence level(k=2). Uncertainty is based on the Total Combined Uncertainty, including uncertainties of characterisation, homogeneity and stability testing. Stability values are based on real evidence opposed to simulation.

Traceability

The balances used for gravimetric measurements are calibrated with weights traceable to the national standards. The calibration of the balances is verified annually by an external accredited calibration service. This analysis method has been verified using an approach consistent with ISO 17034:2016 & ISO 17025:2017.

CERTIFICATE ON	QC SIGNATURE
-		RM Release

Method of Identification

HPLC

Method of Identification

HPLC

Intended Use

This RM is intended for use in a laboratory as a calibration and quality control standard or in method development for analytical techniques.

Storage

This reference material meets the specification stated in this certificate until the expiry date, provided it is stored unopened at the recommended temperature here in. If storage after opening is necessary, the RM should be tightly closed and kept from light and moisture.

Hazards

Read Material Safety Data Sheet (MSDS) and understand any potential hazard(s) prior to the use of this product. All chemicals should be considered potentially hazardous in nature and should only be handled by qualified personnel using established good laboratory practices.

Homogeneity

Random replicate samples of the final packaged RM have been analysed to prove homogeneity compliant with ISO 17034.

Instructions for use

It is recommended to use 1 mg as the minimum sample size and if less material is used, to increase the certified uncertainty by a factor of two for half sample and four for a quarter of sample.Visit the support section of our website technology videos and frequently asked questions.

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

1. 物质的识别

产品名：	Epimedin-B
CAS号：	110623-73-9
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Epimedin-B
分子式：	C38H48O19
分子量：	808.78

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	4°C, protect from light, dry, sealed

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

28. [6.208] Yu Yao et al."A Novel 3-O-rhamnoside: 2″-O-xylosyltransferase Responsible for Terminal Modification of Prenylflavonol Glycosides in Epimedium pubescens Maxim.."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(24):16050

27. [IF=1.698] Jinyan Wu et al."Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS."International Journal of Analytical Chemistry.2022 Oct 15;2022:142380

26. [IF=6.208] Pan Wang et al."Discovery of Flavonoids as Novel Inhibitors of ATP Citrate Lyase: Structure–Activity Relationship and Inhibition Profiles."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(18):10747

25. [IF=5.988] Qihan Luo et al."Chang qing formula ameliorates colitis-associated colorectal cancer via suppressing IL-17/NF-κB/STAT3 pathway in mice as revealed by network pharmacology study."Frontiers in Pharmacology.2022; 13: 893231

24. [IF=4.996] Yuan Jie et al."Systematic characterization of the components and molecular mechanisms of Jinshui Huanxian granules using UPLC-Orbitrap Fusion MS integrated with network pharmacology."Scientific Reports.2022 Jul;12(1):1-24

23. [IF=5.988] Li Pin et al."Epimedium koreanum Nakai–Induced Liver Injury—A Mechanistic Study Using Untargeted Metabolomics."Frontiers in Pharmacology.2022 Jul;0:2288

22. [IF=3.361] Yuhao Zhang et al."An integrated approach for structural characterization of Gui Ling Ji by traveling wave ion mobility mass spectrometry and molecular network."Rsc Adv. 2021 Apr;11(26):15546-15556

21. [IF=3.757] Congyan Liu et al."Enhanced hydrolysis and antitumor efficacy of Epimedium flavonoids mediated by immobilized snailase on silica."Process Biochem. 2019 Nov;86:80

20. [IF=4.411] Zhenxian Qin et al."A Widely Metabolomic Analysis Revealed Metabolic Alterations of Epimedium Pubescens Leaves at Different Growth Stages."Molecules. 2020 Jan;25(1):137

19. [IF=4.545] Yan-dan Zhou et al."Icariin ameliorates cisplatin-induced cytotoxicity in human embryonic kidney 293 cells by suppressing ROS-mediated PI3K/Akt pathway."Biomed Pharmacother. 2019 Jan;109:2309

18. Zhou, Yan-dan, et al. "Icariin ameliorates cisplatin-induced cytotoxicity in human embryonic kidney 293 cells by suppressing ROS-mediated PI3K/Akt pathway." Biomedicine & Pharmacotherapy 109 (2019): 2309-2317.https://doi.org/10.1016/j.biopha.2018.11.108

17. 吴嫣艳,任会旭,冯友龙,张莉,张妤琳.安神补脑胶囊HPLC指纹图谱与3种成分含量测定方法研究[J].广东药科大学学报,2020,36(06):778-783.

16. 黄楷迪,刘敬霞,牛阳,马学琴,张婷,卜凡淑,任慧,郭盛,钱大玮,段金廒.回药扎里奴思方UPLC指纹图谱结合多成分含量测定的质控方法研究[J].南京中医药大学学报,2021,37(01):77-82.

15. 许婷,黄萌萌,李瑞云,杨茹,刘丽芳,陈彦.多基原淫羊藿不同部位质量评价研究[J].中草药,2020,51(01):190-196.

14. 兰海,刘欣妍,余玲,莫诺兰,张燕,郭子右,吴清.大孔树脂纯化淫羊藿中朝藿定与淫羊藿苷工艺研究[J].中草药,2020,51(17):4473-4481.

13. 杨成梓范兴包侠萍等. HPLC同时测定芪骨胶囊中5种成分的含量[J]. 中国实验方剂学杂志 2015 021(016):60-63.

12. 彭静, 马益华, 陈彦,等. 固定化蜗牛酶同时生物转化淫羊藿中4种黄酮苷[J]. 中成药, 2016, 38(9):1984-1990.

11. 高霞, 陈彦, 王莹,等. 糊精湿法制粒对淫羊藿总黄酮酶解的影响[J]. 中成药, 2014, 36(007):1392-1397.

10. 高霞, 刘璇, 陈彦,等. 淫羊藿总黄酮的生物转化过程分析[J]. 中国中药杂志, 2013, 38(23):4079.

9. 刘聪燕, 高霞, 陈彦,等. 淫羊藿总黄酮在骨质疏松大鼠体内的药动学行为[J]. 中成药, 2017, 39(008):1595-1600.

8. 刘聪燕, 高霞, 黄萌萌,等. 淫羊藿总黄酮仿生酶解肠溶胶囊的制备及评价[J]. 中草药, 2016(20).

7. 姜新刚, 贾继明, 李叶双. 津力达颗粒UPLC指纹图谱[J]. 中国实验方剂学杂志, 2013, 19(001):126-129.

6. 张燕. 大孔吸附树脂分离纯化淫羊藿EF5黄酮[J]. 北方药学, 2015, 000(011):11-13.

5. 李婧,王英哲,刘玉翠,景志贤,闫莉,郭俊杰,姜大成,肖井雷.地理环境因子对朝鲜淫羊藿黄酮类成分空间分布影响的探测分析[J].中国中药杂志,2019,44(24):5368-5374.

4. 刘聪燕高霞陈彦等. 仿生酶解肠溶胶囊提高淫羊藿总黄酮口服生物利用度的可行性研究[J]. 中国医药工业杂志 2016(9期):1158-1164.

3. 王英哲姜大成容路生肖井雷张强翁丽丽.东北产朝鲜淫羊藿中黄酮类成分的对比分析[J].药物分析杂志 2019 39(11):2034-2040.

2. 范兴, 杨成梓, 包侠萍,等. 芪骨胶囊HPLC指纹图谱研究[J]. 中草药, 2014, 045(009):1257-1261.

1. 王莹高霞陈彦等. 卡波姆对淫羊藿总黄酮酶解效果的影响[J]. 中国实验方剂学杂志 2014 20(009):1-5.